Delta-Fly Pharma (TSE:4598) Debt-to-Equity : 0.00 (As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Delta-Fly Pharma Debt-to-Equity?

Delta-Fly Pharma's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was 円0.00 Mil. Delta-Fly Pharma's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was 円0.00 Mil. Delta-Fly Pharma's Total Stockholders Equity for the quarter that ended in Dec. 2023 was 円1,689.15 Mil. Delta-Fly Pharma's debt to equity for the quarter that ended in Dec. 2023 was 0.00.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Delta-Fly Pharma's Debt-to-Equity or its related term are showing as below:

During the past 7 years, the highest Debt-to-Equity Ratio of Delta-Fly Pharma was 0.12. The lowest was 0.00. And the median was 0.00.

TSE:4598's Debt-to-Equity is not ranked ^*
in the Biotechnology industry.
Industry Median: 0.14
* Ranked among companies with meaningful Debt-to-Equity only.

Delta-Fly Pharma Debt-to-Equity Historical Data

The historical data trend for Delta-Fly Pharma's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Delta-Fly Pharma Debt-to-Equity Chart

Delta-Fly Pharma Annual Data

Trend

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Debt-to-Equity

Get a 7-Day Free Trial

Delta-Fly Pharma Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															0.12	-	-	-	-

Competitive Comparison of Delta-Fly Pharma's Debt-to-Equity

For the Biotechnology subindustry, Delta-Fly Pharma's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Delta-Fly Pharma's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Delta-Fly Pharma's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Delta-Fly Pharma's Debt-to-Equity falls into.

Delta-Fly Pharma Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Delta-Fly Pharma's Debt to Equity Ratio for the fiscal year that ended in Mar. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	0)	/	791.198
	=	0.00

Delta-Fly Pharma's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	0)	/	1689.151
	=	0.00

Delta-Fly Pharma (TSE:4598) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Delta-Fly Pharma Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Delta-Fly Pharma's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Delta-Fly Pharma (TSE:4598) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Delta-Fly Pharma Inc (TSE:4598) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

Miyajima Kinno 37-5, Tokushima Prefecture, Kawauchi Town, Tokushima, JPN, 771-0116

Website

http://www.delta-flypharma.co.jp

Delta-Fly Pharma Inc is a Japan-based company mainly engaged in the discovery and development of gentle anti-cancer agents with module technology.

Delta-Fly Pharma (TSE:4598) Headlines

No Headlines